CONGRESS PLANNING COMMITTEE
PROGRAM PLANNING COMMITTEE CHAIR
Claude Le Pen PhD, Professor of Health Economics, University of Paris-Dauphine and Expert, IMS Health, Puteaux, Cedex, France

RESEARCH REVIEW COMMITTEE CO-CHAIRS
Gérard De Pouvourville PhD, Professor & Chair of Health Economics, ESSEC Business School, Cergy-Pontoise, France
Andrew Lloyd DPhil, Director, Oxford Outcomes, Oxford, UK

WORKSHOP REVIEW COMMITTEE CO-CHAIRS
Francis Fagnani PhD, Director, CEMKA-EVAL, Bourg la Reine, France
Linus Jonsson PhD, MD, MSc, Vice President Health Economics & Outcomes, i3 Innovus, Stockholm, Sweden

DECISION-MAKER CASE STUDY REVIEW COMMITTEE CO-CHAIRS
Marie-Christine Woronoff-Lemsi PharmD, PhD, Professor, Hospital Pharmacist, CHU de Besançon, Jean Minjoz Hospital, Besançon, Cedex, France
Zbigniew J. Król MD, PhD, Public Affairs and Policy Director, Pfizer Poland, Warsaw, Poland (formerly Deputy Director for Health Technology Assessment, Agency for Health Technology Assessment – AHTAPol)

ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS
Lise Rochaix PhD, Professor, Economics Department, University of Aix-Marseille II, Marseilles, France
Jens Grueger PhD, Vice President, Head Global Market Access Primary Care, Pfizer Ltd., Tadworth, Surrey, UK

24-27 October 2009
Le Palais des Congrès de Paris
PARIS, FRANCE
Health Care Decision Making in Europe: From Patients to Populations

Program
Early Registration Deadline: 8 September 2009

Key Information
Early Registration Deadline: 8 September 2009

Poster Session I: Sunday, 25 October
Set-Up: 11:30-12:00
Poster Display Hours: 12:00-19:30
Poster Author Discussion Hour: 17:30-18:30
Dismantle: 19:30-20:00

Poster Session II: Monday, 26 October
Set-Up: 7:30-8:00
Poster Display Hours: 8:00-19:00
Poster Author Discussion Hour: 17:30-18:30
Dismantle: 19:00-19:30

Poster Session III: Tuesday, 27 October
Set-Up: 7:30-8:00
Poster Display Hours: 8:00-16:00
Poster Author Discussion Hour: 11:00-12:00
Dismantle: 16:00-16:30

Congress Venue
Le Palais des Congrès de Paris
2 Place de la Porte Maillot, 75017 Paris, France
www.palaisdescongres-paris.com
The congress centre is approximately 40 minutes from the Paris-Charles de Gaulle International airport (CDG) and Orly airport (ORY), with close proximity to Paris attractions and served by the Paris Metro.

Hotels Information
An ISPOR delegate rate is available at the Hôtel Concorde La Fayette which is connected to the congress venue. Hôtel Concorde La Fayette 3, Place du Général Koenig, 75017 Paris, France
www.concorde-lafayette.com

ISPOR Rates: The discounted room rate for ISPOR delegates (for 23 – 28 October 2009) is €180 (single) €190 (double), inclusive of taxes, service charges and breakfast. Discounted rates are available until 24 September 2009 (subject to availability).

Reservations: Reservations should be made using the Hôtel Concorde La Fayette online reservation system available at: www.ispor.org. When making your reservation please note the sales and cancellation information, please use the event name: ISPOR.
Program

Saturday 24 October 2009
9:00-18:00 PRE CONGRESS SHORT COURSES

Sunday 25 October 2009
8:00-12:00 PRE CONGRESS SHORT COURSES

13:00-13:15 WELCOME FROM THE ISPOR PRESIDENT & PRESENTATION OF ISPOR SERVICE AWARDS
Michael Barry PhD, 2009-2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital and Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland

13:15-13:30 CONGRESS INTRODUCTION AND OBJECTIVE
Claude Le Pen PhD, Congress Program Planning Committee Chair & Professor of Health Economics, University of Paris-Dauphine and Expert, IMS Health, Puteaux, Cedex, France

13:30-14:45 FIRST PLENARY SESSION
HEALTH CARE REIMBURSEMENT SYSTEMS IN EUROPE: LEARNING FROM EACH OTHER
Health care systems, health technology assessment processes (including economic evaluation), and health policy decision processes (including health technology pricing and reimbursement) vary throughout Europe. During this session, a brief overview of 3 European health care systems and processes (France, Germany, and United Kingdom) will be presented. Then representatives of health authorities from France’s la Haute Autorité de Santé (HAS), Germany’s Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care - IQWiG), and United Kingdom’s National Institute for Health and Clinical Excellence (NICE) will present key issues facing their country’s health care system and processes, including recent, policies, and future initiatives (including the use of economic evaluation information in real decision-making by authorities). Health care authority collaborative initiatives in Europe will also be discussed. For more information on these European country health care systems and health care decision processes, see the ISPOR Global Health Care Systems Road Map at: http://www.ispor.org/THARoadMaps/

Default.asp and http://www.ispor.org/HTARoadMaps/index.asp
Moderator: Claude Le Pen PhD, Professor of Health Economics, University of Paris-Dauphine and Expert, IMS Health, Puteaux, Cedex, France
 Speakers: Laurent Degenis MD, PhD, Chairman, Haute Autorité de Santé (HAS), Saint-Denis La Plaine, Cedex, France; Sir Michael Rawlins MD, PhD, Chairman, National Institute of Health & Clinical Excellence (NICE), London, UK; Peter Sawicki MD, PhD, Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

15:15-16:15 WORKSHOPS AND ISPOR CHAPTER FORUMS – SESSION I
ECONOMIC OUTCOMES RESEARCH

W1: USING A CATALOGUE OF EQ-5D SCORES TO MODEL QALYS FOR COST-EFFECTIVENESS ANALYSES
Discussion Leaders: Patrick W. Sullivan PhD, Associate Professor, Regis University, Rueckert-Hartman College for Health Professions, Denver, CO, USA; Mark J Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Vaheem H Gushchyan PhD, Professional Research Assistant, Pharmaceutical Outcomes Research Program, University of Colorado Denver, Aurora, CO, USA; Julia F Sljeko BA, PhD Student, Pharmaceutical Outcomes Research Program, University of Colorado Denver, Aurora, CO, USA

W2: QUANTIFYING THE RISK IN RISK SHARING: COLLECTING AND MODELING OUTCOMES OF THE NEW ACCESS STRATEGIES
Discussion Leaders: J Jaime Caro MDCM, FRCP, FACC, Senior Vice President, Health Economics, United BioSource Corporation, Health Care Analytics, Lexington, MA, USA; Zeba M Khan RPh, PhD, Vice President Pricing and Market Access, Celgene Corporation, Summit, NJ, USA; Ian Joseph BA, Research Associate, United BioSource Corporation, Health Care Analytics, Lexington, MA, USA

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W3: ORPHAN DRUG FUNDING: A MODEL FOR PERSONALIZED MEDICINE?
Discussion Leaders: Deirdre Mladis BA, Global Head, R&I Health Solutions, Research Triangle Park, NC, USA; Salome de Cambra MD, MBA, Senior Consultant, R&I Health Solutions, Barcelona, Spain; Antoni Gilabert MR, Head of Pharmaceutical Care Management Office, Catalan Health Service, Barcelona, Spain; Eric C Faulkner MPH, Senior Director, Pricing & Reimbursement, R&I Health Solutions, Research Triangle Park, NC, USA

W4: COMPARING APPLES AND ORANGES: USING CONJUNCT-ANALYSIS DATA TO OBTAIN SEVEN QUANTITATIVE BENEFIT-RISK MEASURES
Discussion Leaders: A. Brett Hauber PhD, Senior Economist and Global Head, Health Preference Assessment, R&I Health Solutions, Research Triangle Park, NC, USA; F Reed Johnson PhD, Senior Fellow and Principal Economist, Health Preference Assessment, R&I Health Solutions, Research Triangle Park, NC, USA; John FP Bridges PhD, Assistant Professor, Bloomberg School of Public Health, Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA

W5: SYMPTOM ASSESSMENT IN CLINICAL TRAILS – BRIDGING THE GAP BETWEEN EMA AND FDA
Discussion Leaders: Ingela Wiklund PhD, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, London, UK; Olivier Chassany MD, PhD, Medical Leader, Département de la Recherche Clinique et du Développement, Assistance Publique - Hopitaux de Paris, France; Alastair Glendenning PhD, Health Economics and Outcomes Research, Novartis Pharma, Horsham, West Sussex, UK

USE OF REAL WORLD DATA

W6: THE ROLE OF PATIENT REGISTRIES IN EVIDENCE DEVELOPMENT: SIMILARITIES AND DIFFERENCES BETWEEN EUROPE AND NORTH AMERICA
Discussion Leaders: Eric K Gemmen MA, Senior Director, Medical Affairs, Epidemiology & Outcomes Research, Late Phase & Safety Services, Quintiles, Inc, Falls Church, VA, USA; Chris L Pashos PhD, Vice President, Health Economic Research & Quality of Life Evaluation Services (HERQLES), Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA; Carl J Gibbons BSc, (Psych), Research Analyst, Health Technology Assessment Group, Schering-Plough Ltd, Welwyn, Garden City, UK; Christopher M. Blanchette Ph.D, MS, MA, Associate Scientist and Director, Center for Pharmacoeconomics and Outcomes Research, Livelance Respiratory Research Institute, Albuquerque, NM, USA

Monday 26 October 2009
7:00-8:00 EDUCATIONAL SYMPOSIUM
COMPARATIVE EFFECTIVENESS: CAN THE AGENCIES’ DEMANDS BE MET?
Despite demand from decision-makers and citizens for stronger evidence to support coverage, prioritization and pricing decisions there is no common approach to comparative effectiveness research. This symposium will explore the views of three major agencies NICE, HAS and IQWIG on data requirements, methods, funding and stakeholder roles and debate if a unified approach is possible or even desirable.
(Sponsored by UBC)

8:00-8:30 EXHIBIT & RESEARCH POSTER PRESENTATION VIEWING – SESSION II

8:30-9:45 SECOND PLENARY SESSION
PERFORMANCE-BASED AGREEMENTS – THEORY TO PRACTICE
Health care performance-based agreements are agreements between a party who agrees to provide a health care product (drug or medical device) or a service (doctors to patients) to another party (the payer of the product or service) in which there are uncertainties of its real value. The provider has sufficient

ISPOR 12TH ANNUAL EUROPEAN CONGRESS
24-27 October 2009 | Le Palais des Congrès de Paris | Paris, France
program
reimbursement, or funding conditions in the context of local budget constraints and relevant alternative treatment options. Satisfying both regulatory and HTA requirements creates a large and increasing burden on patients in terms of potentially delayed access and on innovative pharmaceutical manufacturers in terms of time, effort and money. Because of their different roles, regulatory reviews and HTAs have to apply different evidentiary and analytical standards. However increasingly, even where regulatory and HTA objectives overlap, standards differ. In these areas, all stakeholders could benefit from a more coordinated approach. The symposium provides the opportunity to discuss ongoing efforts and new initiatives in this field. (Sponsored by European Federation of Pharmaceutical Industries And Associations - EFPIA)

13:00-14:15  THIRD PLENARY SESSION

INVOLVING PATIENTS IN HEALTH CARE DECISIONS

The patient’s perspective is becoming more important in health care policy decisions worldwide. Patient groups, such as “citizen’s councils”, are being included in health technology coverage decisions in some countries. Patients, themselves, are becoming more proactive through patient advocacy groups, (e.g. European Association of Patients) collectively lobbying for patients rights, including access and rights to health care technology in Europe. During this plenary session, a) how views of the general public are incorporated into health care coverage decisions, b) how information from “citizens’ councils” are incorporated into the decision process, and c) the role of patient advocacy groups in health care policy decisions will be presented and debated.

Moderator/Speaker: Ulf Persson PhD, Research Director, The Institute for Health Economics, Lund, Sweden
Speakers: Peter Littlejohns MD, Clinical & Public Health Director, National Institute for Health and Clinical Excellence (NICE), London, UK; European Patient Group representative - TBD

14:15-14:30  ISPOR RESEARCH EXCELLENCE AND RESEARCH PRESENTATION AWARDS

14:45-15:45  WORKSHOPS AND ISPOR CHAPTER FORUMS – SESSION IV

ECONOMIC OUTCOMES RESEARCH

W19: MODELING SLOWLY PROGRESSING CHRONIC DISEASES WITH EXACERBATIONS AND THEIR TREATMENTS: CHALLENGES IN MODELING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Discussion Leaders: Maureen Rutten-van Molken PhD, Associate Professor, Health Economics, Institute for Medical Technology Assessment, Erasmus University and Erasmus MC, Rotterdam, The Netherlands; Talitha Feenstra PhD, Senior Health Economist RIVM and Assistant Professor HTA, Department of Epidemiology, RIVM and Department of Prevention and Health Services Research, University Medical Center Groningen, BiliHoven, The Netherlands; Sixten Borg MSc, Senior Project Manager, The Swedish Institute for Health Economics (IHE), Lund, Sweden

W20: DEVICES & STRATEGIES: HOW CAN HEALTH ECONOMIC EVIDENCE BE LEVERAGED IN ORDER TO DEMONSTRATE THE VALUE OF MEDICAL DEVICES?

Discussion Leaders: Daniel Jackson MSc, Head of Health Economics - EMEA, GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK; Alison Begg PhD, Senior Consultant, Medaxial Group, London, UK; Adam Pitch MSc, Consultant, Medaxial Group, London, UK

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W21: NEW HEALTH CARE SERVICES – THE PATHWAY INTO THE GERMAN SICK FUND MARKET

Discussion Leaders: Olof Pirck PhD, MD, Principal, Health Economics & Outcomes Research, IMS Health, Nuremberg, Germany; Axel C. Mühlbacher PhD, MSc, Professor, IGM Institut of Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany; Frank-Ulrich Fricke PhD, Principal, IMS Health, Nuremberg, Germany

PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH

W22: METHODS OF POOLING DATA FROM PATIENT-REPORTED OUTCOME (PRO) MEASURES FROM GLOBAL TRIALS: IMPLEMENTING RECOMMENDATIONS OF THE ISPOR TASK FORCE

Discussion Leaders: Asha Hareendran PhD, Senior Research Scientist, Health Care Analytics, United BioSource Corporation, London, UK; Angela Williams BSc, RGN, Pricing and Reimbursement Manager, VirPharma Europe, Maidenhead, Berkshire, UK; Tara Symonds PhD, Senior Director, Global Market Access, Outcomes Research, Pfizer Ltd, Sandwich, Kent, UK

CONTINUING EDUCATION

For pharmacists (CPE): This congress is co-sponsored by Purdue University School of Pharmacy and Pharmaceutical Sciences, Division of Continuing Education and ISPOR. Attendees can earn up to 14.75 hours for attending congress sessions, up to 4 hours for a half-day short course, and up to 7.5 hours for a full day short course. Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. To receive the 14.75 contact hours of continuing education credit, pharmacists must attend the entire program and complete all registration and evaluations at its conclusion.

For physicians (CME): This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Purdue University School of Pharmacy and ISPOR. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University School of Pharmacy designates this educational activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)™ for attending congress sessions, up to 4 AMA PRA Category 1 Credit(s)™ for a half-day short course, and up to 7.5 AMA PRA Category 1 Credit(s)™ for a full day short course, toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Please register for CPE and CME using the enclosed Congress Registration Form or via ISPOR’s online Congress Registration. The fee for this service is $65.

CONGRESS PROMOTIONAL/EMPLOYMENT OPPORTUNITIES

EXHIBIT: Register now! Over 1900 attendees in 2008!
ADVERTISE: Advertise in program and schedule of events!
SPONSOR: Give your company increased visibility and prominence.

USE OF REAL WORLD DATA

W23: THE EMERGING ROLE OF OBSERVATIONAL DATA IN EVALUATING PRODUCT VALUE AND PRODUCT SAFETY

Discussion Leaders: Jerome Wilson PhD, Senior Scientific Affairs Director, PRA, Rockville, MD, USA; Thomas F Goss PharmD, Vice President, Boston Healthcare Associates, Inc.; Washington, DC, USA; Mark R Vanelli MD, MHS, MBA, Chief Medical Officer, Adheris Inc, Burlington, MA, USA

W24: POST-REIMBURSEMENT STUDIES ASSESSING GOOD MEDICATION USE IN REAL PRACTICE: FRENCH SITUATION

Discussion Leaders: Emmanuelle Prieaud PharmD, MSc, Research Manager, Health Outcomes and Market Access, Mapi Values France, Lyon, France; Juliette Longin PhD, MSc, Associate Director, Scientific Expertise and Proposal Development, Registrat-Mapi, Lyon, France; Stéphanie Tcherny MD, MSc, Responsible Researche in pharmacoeconomie et pharmacopédiologie, Unité Pharmacopédiologie – Département médical, Lilly France, Suresnes, France

ISPOR CHAPTER FORUM

QUALITY OF LIFE AND KNOWLEDGE ABOUT TOBACCO SMOKING TOXICITY AMONG SMOKERS OR SMOKERS WITH CHRONIC OBSTRUCTIVE LUNG DISEASES IN POLAND AND GREECE

Presented by the ISPOR Poland and Greece Chapters

16:00-17:00  WORKSHOPS – SESSION V

ECONOMIC OUTCOMES RESEARCH

W25: USING EARLY ECONOMIC MODELLING TO INFORM STRATEGIC PRICING AND CLINICAL STUDY DESIGN

Discussion Leaders: Adam C Lloyd MPhil, Senior Principal, Health Economics and Outcomes Research, IMS Health, London, UK; Michael Chambers MSc, Director of Health Economics, Global Health Outcomes, GlaxoSmithKline, Uxbridge, UK; Joe Caputo BSc, Engagement Manager, Health Economics and Outcomes Research, IMS Health, London, UK

W26: PRAGMATIC SELECTION OF APPROPRIATE MODELLING APPROACH IN PHARMACOECONOMIC EVALUATION

Discussion Leaders: Sandrine Cure MSc, Project Leader, l3 Innovus, Uxbridge, Middlesex, UK; Lee Moore MSc, Health Economist, Roche Products Limited, Welwyn Garden City, Hertfordshire, UK; David Thompson PhD, Vice President, Global Health Economics, l3 Innovus, Medford, MA, USA

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH

W27: VALUE-BASED PRICING OF NEW DRUGS IN JAPAN USING THE PRINCIPLE OF INCREMENTAL COST-EFFECTIVENESS RATIO

Discussion Leaders: Isao Kamada MD, DrPH, Professor, Graduate School of Health Management, Keio University, Fujisawa, Kanagawa, Japan; Makoto Kobayashi MEng, Manager, Health Economics Research Group, Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan

PATIENT-REPORTED OUTCOMES/PREFERENCE-BASED RESEARCH

W28: RECENT PROGRESS ON BEST-WORST SCALING: HEALTH-RELATED APPLICATIONS

Discussion Leaders: Terry N Flynn PhD, Senior Research Fellow, Centre for the Study of Choice (CenSoC), University of Technology Sydney, Sydney, NSW, Australia; Jordan J Louviere PhD, Professor, Centre for the Study of Choice (CenSoC), University of Technology Sydney, Sydney, NSW, Australia; Emma McIntosh PhD, Senior Research Officer, Health Economics Research Centre, University of Oxford, Oxford, Oxfordshire, UK

USE OF REAL WORLD DATA

W29: PRACTICAL APPLICATIONS OF OBSERVATIONAL STUDIES IN TODAY’S MULTI-FACETED, PERI-APPROVAL ENVIRONMENT

Discussion Leaders: Matthew Gordon BA, Director, Lifecycle Sciences Group, ICON Clinical Research, Chicago, IL, USA; Ehab Hasan MPH, Project Manager, Lifecycle Sciences Group, ICON Clinical Research, Chicago, IL, USA; Zaher El-Assi BA, Global Senior Director, Kika Medical, Boston, MA, USA

W30: TECHNIQUES FOR LINKING ADMINISTRATIVE CLAIMS AND EMBRACE-DATA SOURCES

Discussion Leaders: Erica Danielson PhD, Healthcare Research Manager, GE Healthcare Clinical Data Systems, Hillboro, OR, USA; Stacey R Long MS, Vice President, Thomson Reuters, Hampden, ME, USA

PROGRAM

Register now! Over 1900 attendees in 2008!
ADVERTISE: Advertise in program and schedule of events!
SPONSOR: Give your company increased visibility and prominence.

ADVERTISING DEADLINE: 11 SEPTEMBER 2009 / FOR FURTHER INFO VISIT: WWW.ISPOR.ORG

*NEW* Online Professional Recruitment Center - ePRAP
A secure internet based system available only to ePRAP registrants. This service provides easy registration, convenient email communication and online access for candidates applying for positions and employers looking to fill positions.
SATURDAY 24 OCTOBER – ALL DAY (9.00-18.00)

Health Economics/Pharmacoeconomics for Decision-Makers
Faculty: Lieven Annemans PhD, MSc, Ghent University, Belgium
Description: This course offers the opportunity to incorporate pharmacoeconomics into study design and data analysis. Participants learn how to collect and calculate costs of different alternatives, determine the economic impact of clinical outcomes, and identify, track, and assign costs to different types of health care resources used. The development of economic protocols and pharmacoeconomic models and techniques will be demonstrated and practiced. This is an introductory course.

Discrete Event Simulation for Economic Analyses
Faculty: J. Jaime Caro MDCM, FCRPC, FACP, United BioSource Corporation, USA; Jörgen Möller MSc Mech Eng, United BioSource Corporation, Sweden
Description: This course provides a basic understanding of the key concepts of discrete event simulation. Topics to be covered are: Why DES? Dynamic simulation as a tool; Components of a DES; How do you build a model? Modeling of processes and resource use; Modeling of variables and decisions. This is an intermediate course.

SATURDAY 24 OCTOBER – MORNING (9.00-13.00)

Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluation
Faculty: Andrew Lloyd DPhil, Oxford Outcomes, UK; Diane Wild MSc, Oxford Outcomes, UK
Description: Instrument development and evaluation includes psychometric analyses such as the use of factor analysis and other techniques. This course will cover the recent draft guidance from the FDA as well as existing guidance from the EMEA regarding instrument development. This course is designed for those with some experience using PR instruments.

Elements of Pharmaceutical/Biotech Pricing I – Introduction
Faculty: Jack Mycka, MMIE LLC, USA; Renato Dellamano PhD, ValueVector (Value Added Business Strategies), Italy
Description: This course gives participants a basic understanding of the key terminology and issues involved in pricing decisions. It covers the tools to build and document product value, the role of pharmacoeconomics and the differences in payment systems that help to shape pricing decisions. This course is designed for those with limited experience in pharmaceutical pricing.

Pharmacoeconomic Modeling
Faculty: Uwe Siebert MD, MPH, MSc, ScD, University of Health Sciences, Medical Informatics and Technology, Austria
Description: This course presents an introductory discussion of pharmacoeconomic modeling techniques such as Monte Carlo analysis, Markov modeling, and probabilistic sensitivity analysis. This is an introductory course.

Introduction to Statistics
Faculty: Andrew Briggs PhD, University of Glasgow, Scotland
Description: This course begins by discussing the foundations upon which major statistical tests are based and the application of these tests to pharmacoeconomic problems, and continues with detailed instruction for the use and application of statistical software, allowing students the opportunity for hands-on practice. This is an introductory level course.

European Databases and Retrospective Database Analysis
Faculty: Elise Pelletier MSc, IMS Health Consulting, USA
Description: This course takes a methodological approach to the practical usage of existing patient databases and selected topics related to estimators, sampling distributions and ordinary least squares regression. More complex topics such as endogeneity, identification, and limited dependent variables are discussed. This course assumes knowledge of statistical methods and understanding of the analysis of administrative patient databases.

SATURDAY 24 OCTOBER – AFTERNOON (14.00-18.00)

Meta-Analysis & Systematic Literature Review
Faculty: Neil Hawkins PhD, MSc, University of York, UK; Olivia Wu PhD, MSc, University of Glasgow, UK
Description: A systematic literature review often includes meta-analysis and involves an explicit, detailed description of how a review was conducted. This course highlights and expounds upon four key areas: 1) impetus for meta-analysis and systematic reviews; 2) basic steps to perform a quantitative systematic review; 3) statistical methods of combining data; and 4) appraisal and use of meta-analytic reports. This is an introductory level course.

Bayesian Methods in Economic Evaluations
Faculty: Keith R. Abrams PhD, University of Leicester, UK
Description: This course is designed to provide an overview of the Bayesian approach. It will cover basic elements of Bayesian statistics, discuss differences between Bayesian and classical approaches, and demonstrate how to apply the Bayesian approach to clinical trials and cost-effectiveness analyses. This course is for those with a basic appreciation of statistics and probability.

Utility Measurements (Preference-Based Techniques)
Faculty: Jan Busschbach PhD, Erasmus Medical Center, The Netherlands
Description: Methods for measuring preference-based outcomes are demonstrated, and important issues are discussed, such as: potential insensitivity of generic instruments for disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. Finally we turn to the interpretation in the context of resource allocation. This course is for those with some experience with quality-of-life measures in health economic evaluation.

Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies
Faculty: Josephine Mauskopf PhD, RTI Health Solutions, USA; C. Daniel Mullins PhD, University of Maryland School of Pharmacy, USA
Description: This course describes methods to determine the costs associated with a health condition and the budget impact of new technologies for that condition, and presents incidence- and prevalence-based costing strategies. Treatment algorithms and event-based approaches are demonstrated. Static and dynamic methods for estimating the budget impact of adding a new drug to a health plan formulary are presented. This course is for those with some experience with pharmacoeconomic analysis.

Reimbursement Systems in Europe
Faculty: James Furniss, Bridgehead International Limited, UK; Kevin W. Mayo PhD, Bridgehead U.S.A.; USA; Sasha Richardson PT, Bridgehead International Consulting, UK
Description: This course is designed to provide participants with an understanding of the various procedures employed by European health authorities to regulate market access based upon the appraisal of the clinical and in some countries economic value of new medical technologies. The faculty will describe the reimbursement legislation, processes and organizations within each nation and describe the role of the pharmaceutical and/or medical device manufacturer. This course is designed for individuals with intermediate experience within a single health care system.

Transferability of Cost-Effectiveness Data between Countries
Faculty: JL Severens PhD, Maastricht University, The Netherlands; SMAA Evers PhD LL.M, Maastricht University, The Netherlands; MA Joore PhD, University Hospital Maastricht, The Netherlands
Description: This course discusses factors that make economic data more difficult to transfer from one country to another than clinical data, and the evidence on the variability of cost-effectiveness results across countries. We will review the methods that offer a solution and their pros and cons. Finally, we will discuss emerging international guidance for dealing with issues of transferability. This is for those with basic understanding of cost calculation and modeling.

Cost-Effectiveness Analysis alongside Clinical Trials
Faculty: Scott Ramsey MD, PhD, Fred Hutchinson Cancer Research Center, USA; Richard Wilkie PhD, Pfizer, Inc., USA; Sean Sullivan PhD, RPh, MS, University of Washington, USA
Description: This course will present the design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials. Trial design, selecting data elements, database design and management, analysis, and reporting of results will be presented. This is an introductory/intermediate level course.

Pharmaco-economic Modeling – Advanced
Faculty: Uwe Siebert MD, MPH, MSc, ScD, University of Health Sciences, Medical Informatics and Technology, Austria; Alexander Göhler MD, Harvard Medical School, USA
Description: The course covers practical steps involved in the selection and modeling of data inputs and practical aspects related to the determination of when, why and how to handle stochastic and probabilistic uncertainty. This is an advanced course.

Advanced Patient-Reported Outcomes Assessment: Psychometric Methods
Faculty: Cheryl Hill PhD, RTI Health Solutions, USA; Mark Price MA, MEd, RTI Health Solutions, USA
Description: This course will discuss psychometric analysis and the application of various techniques (structural equation modeling, factor analysis, and item response theory) in testing patient-reported outcomes instruments, measures and construct criterion validation. This is an advanced course.

Propensity Scores and Comorbidity Risk Adjustment
Faculty: Fadia Shaya MPH, PhD, University of Maryland School of Pharmacy, USA
Description: This course outlines the concerns about bias and explains the methods for causal inference in observational studies. We discuss how propensity scores can be used to reduce bias. Confounding and the pros and cons of standard adjustment, propensity scoring methodology and risk adjustment models will also be discussed. This is an introductory course.
## ISPOR Short Course Registration

- **Saturday, 26 October | All Day (9:00 - 18:00)**
  - Health Economics/Pharmacoconomics for Decision-Makers (must provide current enrollment documentation)
  - Discrete Event Simulation for Economic Analyses

- **Saturday, 26 October | Morning (9:00 - 13:00)**
  - Introduction to Patient-Reported Outcomes Assessment: Instrument Development & Evaluation
  - Elements of Pharmaceutical/Biotech Pricing
  - Pharmacoconomic Modeling
  - Introduction to Statistics
  - European Databases & Retrospective Database Analysis

- **Saturday, 26 October | Afternoon (14:00 - 18:00)**
  - Meta-Analysis & Systematic Literature Review
  - Bayesian Methods in Economic Evaluations
  - Utility Measurements (Preference-Based Techniques)
  - Cost Estimation & Assessing Financial (Budget) Impact of New Health Care Technologies
  - Introduction to Health Technology Assessment
  - Reimbursement Systems in Europe
  - Transferability of Cost-Effectiveness Data between Countries
  - Cost-Effectiveness Analysis alongside Clinical Trials
  - Pharmacoeconomic Modeling – Advanced
  - Advanced Patient-Reported Outcomes Assessment: Psychometric Methods
  - Propensity Scores & Comorbidity Risk Adjustment

### Half Day Short Course Fees

<table>
<thead>
<tr>
<th>Registration Before September 8: REGULAR</th>
<th>$115</th>
<th>$164</th>
<th>STUDENT</th>
<th>$65</th>
<th>$78</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration After September 8: REGULAR</td>
<td>$150</td>
<td>$213</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### All Day Short Course Fees

<table>
<thead>
<tr>
<th>Registration Before September 8: REGULAR</th>
<th>$230</th>
<th>$327</th>
<th>STUDENT</th>
<th>$115</th>
<th>$164</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration After September 8: REGULAR</td>
<td>$300</td>
<td>$427</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ISPOR Congress Registration

- **Standard**
  - Registration Before 8 September: $500
  - Registration After 8 September: $600

- **Clinical Practitioners (Clinical Practice, Hospital)**
  - Registration Before 8 September: $350
  - Registration After 8 September: $450

- **Full-Time Government and Academia**
  - Registration Before 8 September: $250
  - Registration After 8 September: $350

- **Full-Time Students** (must provide current enrollment documentation)
  - Registration Before 8 September: $100
  - Registration After 8 September: $150

### One Day Registration (per day)**

- **25 Oct**: $65
- **26 Oct**: $65
- **27 Oct**: $65

### Continuing Education Accreditation

- $65
- $65
- $65

### ISPOR Social Event

- $100

**Social Event Fee Subject to Change**

## Registration Fees

<table>
<thead>
<tr>
<th>QTY</th>
<th>FEE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SHORT COURSE ALL DAY REGISTRATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SHORT COURSE HALF DAY REGISTRATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISPOR SOCIAL EVENT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONTINUING EDUCATION ACCREDITATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CONGRESS REGISTRATION</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL REGISTRATION FEE:**

### Payment Information

Please enclose a check payable in US dollars or Euro € to: International Society for Pharmacoconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: VISA MasterCard American Express Account Number: __________ Expiration Date: __________

Name: ____________________________

Authorized Signature: ____________________________

Mail Details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoconomics and Outcomes Research, 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA Tel: 1-609-219-0773 Fax: 1-609-219-0774 • E-Mail: info@ispor.org • Internet: www.ispor.org

Payment Details: Payment may be made by check, travelers check, bank transfer (there is a USD $40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US$ on banks with a US counterpart are at no charge. For Non-US checks written in US$ on banks with NO US counterpart there is USD $25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate the registration name and/or registration number.

Membership Details: If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. The Non-Member rate includes an annual ISPOR membership ($140/$35 Students), which includes a one year online subscription to Value in Health – The Journal of the International Society for Pharmacoconomics and Outcomes Research. One day registration is excluded. The fees are adjusted accordingly.

*The Non-Member rate includes an annual ISPOR membership ($140/$35 Students).

**One day registration is excluded. The fees are adjusted accordingly.

Cancellation Details: Cancellation fee before 8 September 2009 is US $145. No refunds given after 8 September 2009.